FDA OTC Advantage Unique FDA 510(k) clearance for an OTC diagnostic smartphone app positions Scanwell as a compelling partner for retailers, pharmacies, and insurers looking to add consumer-facing at-home tests.

Strategic BD Partnering BD's acquisition and ongoing collaboration establish Scanwell as a foundational digital platform for at-home diagnostics, creating opportunities for co-development, white-labeling, and joint go-to-market deals with large medtech players.

Infectious Disease Expansion The portfolio focus on rapid at-home tests for SARS-CoV-2 and influenza A+B suggests a scalable path to broader infectious disease testing with healthcare providers and employers seeking remote screening programs.

Tech Integration Ready A modern tech stack including mobile apps, cloud services, and machine learning enabled test interpretation enables easy integration with EMR/EHR, patient portals, and analytics platforms, creating opportunities with health systems and digital health platforms.

Growth via Partnerships BD backed company status and past acquisition validation position Scanwell to pursue channel partnerships, OEM arrangements, and distribution agreements to accelerate market penetration in clinics, retail, and workplace health.